Since start of commercial distribution in June 2016, CLINUVEL has reached annual profitability and positive net cash flows. The Company is self-sufficient, distributing its lead product SCENESSE® in the US and EU for a genetic disorder porphyria (EPP). The Company has paid annual dividends since 2018.
Five year Revenue and NPBT CAGR, 31.3% and 37.0%, respectively. NPAT (of A$11.4 million) for the six months to 31 December 2022 was the highest for a December half year, and the 14th consecutive half year profit. The balance sheet is strong and growing; debt-free and cash reserves of A$141 million, exceeding four times FY2022 expenses. This position enables management to manage the challenging operational environment, and self-finance organic expansion. No dilutive capital raisings since March 2016.
Total 70 employees, an executive management team of 9 (median tenure of 15 years). Gender diversity throughout Board and firm.
In-house functions: R&D, regulatory, clinical, market access, distribution, pharmacovigilance, communications, branding and marketing, and finance.
Overcoming two decades of challenges the firm has pioneered;
its current success is best characterized by:
“Resourcefulness – Longitude – Pre-emption”
Translating melanocortins to commercial products benefiting unmet need.
Establishing a fully integrated house – a pharma division & specialized consumer care; manufacturing; communications, branding & marketing.
|Main Exchange, ASX||CUV|
|Shares on issue||49,410,338|
|Average Daily Trading (last 65 days)||88,259|
|Market Capitalisation||A$1.0 Bn|
|Price Earnings Ratio||47.6|
|Price to Book Ratio||7.9|
|Board and Employees||11.2%|
|American Depositary Receipts||8.7%|
|Top 20 (beneficial) shareholders||60.0%|
Lead melanocortin, SCENESSE® (afamelanotide 16mg)